ASTRAZEN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.1
| Stock Code | ASTRAZEN | Market Cap | 21,126 Cr. | Current Price | 8,436 ₹ | High / Low | 9,850 ₹ |
| Stock P/E | 110 | Book Value | 349 ₹ | Dividend Yield | 0.38 % | ROCE | 29.3 % |
| ROE | 23.3 % | Face Value | 2.00 ₹ | DMA 50 | 8,482 ₹ | DMA 200 | 8,550 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | 0.24 % | PAT Qtr | 45.7 Cr. | PAT Prev Qtr | 31.6 Cr. |
| RSI | 48.2 | MACD | -17.9 | Volume | 7,459 | Avg Vol 1Wk | 4,747 |
| Low price | 7,552 ₹ | High price | 9,850 ₹ | PEG Ratio | 7.42 | Debt to equity | 0.13 |
| 52w Index | 38.5 % | Qtr Profit Var | -26.6 % | EPS | 75.0 ₹ | Industry PE | 32.5 |
📊 Analysis: AstraZeneca (ASTRAZEN) demonstrates strong efficiency metrics with ROE at 23.3% and ROCE at 29.3%, supported by a low debt-to-equity ratio of 0.13. However, the valuation is stretched with a P/E of 110 compared to the industry average of 32.5, and a high PEG ratio of 7.42, indicating limited growth relative to price. Dividend yield remains modest at 0.38%. Technical indicators (RSI 48.2, MACD -17.9) suggest neutral to slightly bearish momentum, while quarterly profit variation (-26.6%) highlights volatility.
💰 Entry Price Zone: A prudent entry range lies between ₹7,550 – ₹8,000, closer to its recent low and below DMA levels, offering better valuation comfort.
📈 Exit / Holding Strategy: Existing holders may continue with a long-term horizon (3–5 years) given strong ROE/ROCE and low leverage. Exit strategy should be considered if price approaches ₹9,800–₹10,000 resistance without earnings catch-up. Long-term investors can hold, but fresh entries should wait for correction.
🔵 Positive
- Strong [ROE](ca://s?q=Explain_ROE) of 23.3% and [ROCE](ca://s?q=Explain_ROCE) of 29.3%.
- Low [debt-to-equity](ca://s?q=Debt_to_equity_ratio) ratio of 0.13 ensures financial stability.
- Quarterly PAT growth (₹45.7 Cr vs ₹31.6 Cr) shows operational strength.
- Institutional confidence with increased [FII](ca://s?q=What_is_FII) and [DII](ca://s?q=What_is_DII) holdings.
🟠 Limitation
- Excessive [P/E ratio](ca://s?q=Explain_PE_ratio) of 110 vs industry average of 32.5.
- High [PEG ratio](ca://s?q=Explain_PEG_ratio) of 7.42 indicates poor growth-to-price alignment.
- Low [dividend yield](ca://s?q=Dividend_yield_explained) at 0.38%.
- Quarterly profit variation (-26.6%) signals earnings volatility.
🔴 Company Negative News
- Valuation remains significantly stretched compared to peers.
- Neutral technical indicators (RSI, MACD) show lack of strong momentum.
🟢 Company Positive News
- Strong quarterly PAT improvement compared to previous quarter.
- Institutional investors increasing stake, signaling confidence in long-term prospects.
🏭 Industry
- Industry P/E at 32.5 highlights peers trading at more reasonable valuations.
- Pharmaceutical sector remains resilient with consistent demand drivers.
📌 Conclusion
ASTRAZEN is fundamentally strong but overvalued at current levels. Long-term holders can continue, while new investors should wait for correction towards ₹7,550–₹8,000. Exit near ₹9,800–₹10,000 if valuations remain stretched without earnings growth.